5 Public Companies Where Legal Risk Could Be Bigger Than Investors Think
Five cases where the real exposure isn't the verdict, it's the blueprint it leaves behind.
Litigation comes in all shapes. Sometimes small, sometimes big, sometimes irritating, and sometimes even lethal.
Public companies know this. Getting sued is just part of operating inside a rule-of-law system. Most cases get absorbed, settled, forgotten by the next earnings call.
But every so often a case isn’t really about the case. It’s about what it unlocks.
Some of these start as nothing. A seed. Then somewhere along the way it turns into poisonous fruit, and by the time a company realizes it swallowed it, the thing is nearly impossible to expel. A few of these prove fatal.
It’s rarely one single thing. It’s the slow accumulation of legal and regulatory pressure that increasingly decides whether a business stays profitable, or stays in business at all. Sometimes it’s a plaintiff verdict big enough to set a precedent. Sometimes it’s a regulator quietly taking a bite out of the moat that made the business valuable in the first place.
Here are five companies I think fit that pattern right now, where the market may be pricing the case in front of it and missing what the case could unlock.
1. BNP Paribas (OTC: BNPQY)
A New York federal jury awarded roughly $20.5 million to three Sudanese plaintiffs who argued BNP Paribas helped enable atrocities under Sudan’s former government by processing sanctions-violating banking transactions. On its own, that’s a rounding error for a bank this size.
The problem is where those three plaintiffs came from: lawyers for the group say the verdict opens the door for more than 20,000 refugees in the U.S. to pursue billions in additional claims. BNP has called the result wrong and is appealing to the Second Circuit, after already losing a bid to have the verdict thrown out at the district court level.
The market seems to be betting the appeal holds or the case settles quietly for something manageable. But if an appellate court lets the liability theory itself survive, the question stops being “what’s this verdict worth” and becomes “how many times can this verdict be copied.” That’s a different number entirely.
Investor takeaway: Watch the Second Circuit, not the $20.5 million number. That figure is irrelevant. What matters is whether the appeals court lets the underlying legal theory stand. If it does, the real number shows up in how many of those 20,000+ refugees can now file the same claim.
2. BHP Group (NYSE: BHP)
A lot of investors treat the Samarco dam disaster as old news, settled and priced in after Brazil’s compensation process wrapped up. The parallel case working through the UK might not let them off that easily.
England’s High Court has already found BHP liable in what’s being called the largest group litigation ever brought in the UK, with more than 620,000 claimants seeking damages estimated at up to £36 billion; what’s left to fight over is how much, and how much credit BHP gets for what it already paid out in Brazil. BHP has indicated it will appeal, and one analyst quoted at the time called the ruling largely symbolic given BHP had already provisioned $5.5 billion under its 2024 Brazil agreement.
The assumption embedded in BHP’s share price is that Brazil closed the book financially. If the English court decides large chunks of damage were never actually compensated, that assumption breaks, and investors have to ask whether the “settlement” was ever really the ceiling.
Investor takeaway: Don't expect this to hit the stock soon. Any real cash impact is years out, 2029 or later on current estimates. This is a slow-burn risk, not a next-quarter one. What to track: the next phase of the UK case, where the court decides how much BHP actually owes on top of what it already paid in Brazil.\
3. UnitedHealth Group (NYSE: UNH)
UnitedHealth’s Medicare Advantage business runs on coverage decisions made at scale, and a federal lawsuit argues one of the tools making those decisions wasn’t fit for the job. The case centers on nH Predict, an algorithm built by UnitedHealth subsidiary naviHealth that plaintiffs say was used to cut off post-acute care, sometimes overriding what treating physicians recommended. The complaint cites a striking number: among patients who appealed a denial, roughly nine out of ten won. UnitedHealth says the tool is a planning guide, not a coverage-decision engine, and that medical directors make the actual calls.
A judge let the case move forward in February 2025, and in March 2026 ordered UnitedHealth to turn over broad internal records on how the algorithm was designed and deployed, including performance reviews tied to keeping patient stays close to the algorithm’s predictions. UnitedHealth isn’t the only insurer facing this exact theory: Cigna and Humana are defending nearly identical claims over their own denial algorithms.
The market’s assumption is that this stays a UnitedHealth-specific headache, a bad-PR story about one flawed tool. But the underlying legal theory, that leaning on an algorithm to make coverage calls can itself be bad faith, doesn’t care which insurer’s logo is on it. If a court validates that theory against UnitedHealth, it becomes a template the other insurers’ plaintiffs can borrow directly. That’s a liability question for the whole Medicare Advantage business model, not a one-off lawsuit.
Investor takeaway: This isn't really a UnitedHealth problem. It's an industry problem wearing one company's name. Cigna and Humana are fighting the exact same fight over their own AI denial tools. If a court rules against UnitedHealth's algorithm, expect that ruling to get used against the other two next.
4. Snap (NYSE: SNAP)
When people talk about youth-addiction lawsuits against social platforms, Meta absorbs almost all the attention. Snap is exposed to a lot of the same legal theories; it just has a fraction of Meta’s balance sheet to absorb the impact.
Thousands of these cases (more than 10,000 individual claims and nearly 800 school-district lawsuits) are working through a federal multidistrict litigation, and Snap has already settled with at least one plaintiff on the eve of trial rather than let a jury weigh in, while Meta went to trial and lost, paying a combined $6 million in the first bellwether case. The market’s implicit bet is that whatever damages come out of this, they’ll land mostly on Meta.
But if courts start endorsing the underlying theory (that recommendation algorithms and engagement mechanics are themselves the defective product), that theory doesn’t care how big your market cap is. It could end up costing Snap disproportionately more relative to its size, precisely because it has less room to absorb it.
Investor takeaway: Pay attention to what Snap is doing, not just what it's saying. Settling a case before a jury ever sees it is a tell. Companies don't pay to make weak cases go away. Keep an eye on the big Meta trial starting in Oakland this August. However that one goes sets the tone for every case still in line behind it, Snap included.
5. Alphabet (NASDAQ: GOOGL)
Alphabet has lost enough legal battles by now that investors have stopped treating any single one as a big deal. That track record may be breeding complacency it doesn’t deserve.
Investors tend to bucket Android, Search, Ad Tech, Shopping, and AI interoperability as separate legal fights, each contained to its own case. Courts are increasingly not seeing it that way; they’re treating these as connected exercises of the same underlying market power. In July 2026, the European Commission ordered Google to share anonymized search data with rivals and open Android to competing AI assistants, moving well past fines into structural remedies. That came just weeks after Google lost its appeal of a $4.1 billion EU antitrust fine over Android. On top of that, a U.S. judge separately ordered Google to share search data with competitors in the DOJ’s search-monopoly case.
The market’s assumption is that each case is financially survivable in isolation. The actual risk isn’t one massive judgment that changes everything overnight. It’s several remedies chipping away at the same competitive advantages from different directions at once. At that point, you’re not pricing lawsuits anymore. You’re pricing a structural shift in how the business operates.
Investor takeaway: No single ruling here will move the stock, and that's the trap. Watch these as a group, not as individual headlines. Every time Alphabet gets forced to open up its data or its platform to competitors, a little more of what made Google valuable gets handed to someone else. That adds up slowly, not all at once.
Bottom Line
A big verdict rarely moves a stock on its own. A reusable legal theory does.
Each of these five companies is fighting a different kind of case, but they share the same underlying risk: a single ruling that becomes the template for a much bigger liability than what’s currently priced in. Whether that actually plays out is genuinely uncertain. Appeals, settlements, and regulatory decisions could all defuse it. But the question worth asking isn’t “how big is today’s verdict.” It’s “how many more times can today’s legal theory get used.”
Editorial note: This article presents a probabilistic interpretation of litigation, regulatory and commercial incentives based on publicly available information. The confidence level applies only to the behavioral scenario described above. It is not a prediction of any company’s share price, financial performance or final court result, and it is not legal, financial or investment advice. Litigation, appeals, settlements and regulatory actions remain uncertain, and new facts could materially change the analysis.